In Spain, the results from the CART19-BE-01 clinical trial evaluating the safety and efficacy of the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel, ARI-0001 cells) (8, 9), led to its extraordinary approval, as Hospital Exemption, by the Spanish Agency of Medicines (AEMPS) for patients older than 25 years of age with R/R ALL (10). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.